266 related articles for article (PubMed ID: 2499293)
1. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
Windyga J; Rzymkiewicz L; Lopaciuk S
Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440
[TBL] [Abstract][Full Text] [Related]
4. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
[TBL] [Abstract][Full Text] [Related]
5. [Outcome of hemorrhage treatment in children with hemophilia A related to factor VIII inhibitor].
Klukowska A; Zieleniewska B
Acta Haematol Pol; 1994; 25(4):349-54. PubMed ID: 7847036
[TBL] [Abstract][Full Text] [Related]
6. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
Meili EO; Dazzi H; von Felten A
Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
[TBL] [Abstract][Full Text] [Related]
7. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
8. Treatment of anti-factor VIII antibodies.
Blatt PM; White GC; McMillan CW; Roberts HR
Thromb Haemost; 1977 Aug; 38(2):514-23. PubMed ID: 579493
[TBL] [Abstract][Full Text] [Related]
9. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies.
Gatti L; Mannucci PM
Thromb Haemost; 1984 Jul; 51(3):379-84. PubMed ID: 6437005
[TBL] [Abstract][Full Text] [Related]
10. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
11. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
Sjamsoedin LJ; Heijnen L; Mauser-Bunschoten EP; van Geijlswijk JL; van Houwelingen H; van Asten P; Sixma JJ
N Engl J Med; 1981 Sep; 305(13):717-21. PubMed ID: 6790990
[TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors in young boys with haemophilia.
Lusher JM
Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J
Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361
[TBL] [Abstract][Full Text] [Related]
17. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.
Nilsson IM; Berntorp E; Zettervall O
N Engl J Med; 1988 Apr; 318(15):947-50. PubMed ID: 3127711
[TBL] [Abstract][Full Text] [Related]
18. Lack of immune response to mouse IgG in hemophilia A patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIII preparation.
Davis HM; Brown SK; Nash DW; Pennetti AM; Salzman PM; Schreiber AB; Haimovich J
Thromb Haemost; 1990 Jun; 63(3):386-91. PubMed ID: 2119524
[TBL] [Abstract][Full Text] [Related]
19. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.
Schwartz RS; Abildgaard CF; Aledort LM; Arkin S; Bloom AL; Brackmann HH; Brettler DB; Fukui H; Hilgartner MW; Inwood MJ
N Engl J Med; 1990 Dec; 323(26):1800-5. PubMed ID: 2123300
[TBL] [Abstract][Full Text] [Related]
20. New protocol for immune tolerance induction in acquired hemophilia.
Nemes L; Pitlik E
Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
